



## Press Release

### Athena Capital Partners Assists Albiorex with Capital Raise

**Tampa, FL** - July 21, 2009 - Athena Capital Partners, Inc., a Tampa based investment bank, has been retained by Albiorex, Inc., a biotechnology medical device company, to extend the company's successful \$2.0 million B Round Capital Raise (2008) and allow for the sale of an additional \$2.5 million in Series B shares.

"Our premier product, Humallagen™, is within weeks of completion of a pilot FDA clinical trial and we are looking forward to presenting the results of this trial to our current and future shareholders. Albiorex believes that until the creation of our initial product Humallagen™, the ideal dermal filler has not existed - and that Humallagen™ is going to be a strong contender in the dermal filler arena. We are also excited about our tissue engineering patents and products in the pipeline for multiple other fields of use," says Rees Orland, Albiorex CEO.

"Since our initial B Round raise of \$2.0 million in 2008, we have been able to stretch investor dollars to include the development and FDA acceptance for use of our validated scale for the correction of facial defects, received FDA unconditional approval for our Phase II pilot study, produced finished product for trial use, completed the treatment of patients in our FDA approved, randomized single-center, 20 subject double blinded split face trial and begun expansion of the scopes of uses and filed 5 new patent applications. With the \$2.5 million extension of this round, we anticipate to fund operations for the next 24 months, initiate our pivotal trial, continue IP expansion and achieve our pre-revenue milestones. To this end, we have hired Athena Capital Partners to assist us in the extension of our B Round. We have had a long investment banking relationship with Athena and have full faith in their ability to assist us in extending this B Round opportunity."

Kevin T. Cimino, CEO of Athena Capital Partners feels that Albiorex's IP pipeline and FDA study approvals have it

### Quick Links

[www.athena-capital.com](http://www.athena-capital.com)  
[www.albiorex.com](http://www.albiorex.com)

### Industry Expertise

Dealerships  
 Distribution  
 Energy  
 Healthcare  
 Information Technology  
 Insurance  
 Manufacturing  
 Not for Profits  
 Real Estate  
 Restaurants  
 Retail  
 Staffing

**Kevin T. Cimino**  
 CEO and Managing Director  
[kcimino@athena-capital.com](mailto:kcimino@athena-capital.com)

**Sherman F. Taylor**  
 Senior Vice President  
[staylor@athena-capital.com](mailto:staylor@athena-capital.com)

**Paige L. Gunn**  
 Associate  
[pgunn@athena-capital.com](mailto:pgunn@athena-capital.com)

**Joyce E. Hawkesworth**  
 Controller/Analyst  
[jhawkesworth@athena-capital.com](mailto:jhawkesworth@athena-capital.com)

**Kim H. Greiwe**  
 Analyst  
[kgreiwe@athena-capital.com](mailto:kgreiwe@athena-capital.com)

**Athena Capital Partners, Inc.**  
 Post Office Box 18553  
 Tampa, FL 33679-8553  
 (813) 489-4380  
[www.athena-capital.com](http://www.athena-capital.com)

Member FINRA/SIPC

poised for success, "I have been involved with Albiorex since their Series A raise and have witnessed the company's continued growth and progress towards FDA approvals. Their experienced management and board are made up of tissue engineering and dermal filler experts, plastic surgeons and orthopedic surgeons, patent and trial experts. Even before these tight financial times, Albiorex has been focused on the use of capital for the growth and progress of the company, FDA trials and approvals, IP expansion and achievement of milestones. In this challenging economic climate, Athena is extremely selective, taking on only the strongest of clients - something that is typified by Albiorex and their management. We are pleased to continue our investment banking relationship with Albiorex, and look forward to assisting them in reaching their milestones towards FDA approval and product release of Humallagen™."



## About Albiorex

Albiorex is a medical device company with a focus on regenerative medicine. Albiorex's initial product undergoing clinical evaluation for FDA approval is Humallagen™, an injectable dermal filler to be used primarily to correct the appearance of facial defects attributable to natural aging and degeneration. Unlike existing dermal fillers on the market, Humallagen™ is believed to be the first and only "BioActive" dermal filler - having the ability to both restore and regenerate new tissue in-growth with the potential to result in a longer lasting correction of facial wrinkles. Albiorex's bioactive and regenerative discoveries have numerous additional patentable applications including stem cell therapy, follicular unit (hair) replacement, skin grafting, adipose (fat survival) grafting, wound healing, ophthalmology, orthopedic biologics, drug delivery, and tissue regenerative engineering.

## Athena Private Capital Raise Services

In this economic climate, many companies are seeking assistance in raising debt and equity financings for a variety of purposes. Athena is very active in the private placement of equity and debt including:

- Private Placements of Equity
- Subordinated Debt Financings
- Mezzanine Financings
- Asset-based Lines of Credit
- Senior-Term Loans
- Recapitalizations
- Private Investment in Public Entities (PIPEs)

## · Equipment Financing

Our professionals have extensive experience in packaging and marketing companies to qualified targets, negotiating terms and transaction closing. Athena's direct access to thousands of lenders and investors allows us to leverage our relationships to successfully raise private capital on the best available terms for our clients.

Generally we look to partner with profitable businesses ideally having current revenues of \$5 to \$10 million or more.

For smaller companies and those in earlier stages of growth (that are finding it difficult to find investors on their own and are too small for most investment banks to engage) Athena is unique in that we offer specialized Consulting Services for early stage companies. These services may include assistance with the creation of a revenue model, proformas, marketing materials (for fundraising) and suggesting specialized targets or avenues for company management to approach. This assistance allows small or startup companies to be positioned to pursue their first rounds of fundraising, as well as allowing the company to grow large enough for Athena's direct involvement in later rounds.

All client engagements are treated with the utmost confidentiality.

### **About Athena Capital Partners, Inc.**

Athena Capital Partners, Inc. is a licensed investment bank that specializes in: **(1) Merger & Acquisition Services** including recapitalizations, management buyouts, leveraged buyouts, sell-side or buy-side transactions; **(2) Private Capital Raise Services** including growth capital (equity and debt), PIPEs and public-to-private transactions; **(3) Restructuring Services** to distressed companies, including on-site turnaround management, in and out of court restructuring, raising fresh equity or debt capital and selling distressed assets. We also provide trustee and receivership services.

We have a team of seasoned professionals with years of experience in a variety of industries including dealerships, distribution, energy, health care, information technology, insurance, manufacturing, not for profits, real estate, restaurants, retail, staffing and others.

Athena, founded in 2002, is based in Tampa, Florida.

This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The parties may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and investors should not place undue reliance on the forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements made by the parties. Important factors that could cause actual results or events to differ materially from the forward-looking statements. Athena assumes no obligation to update any forward-looking statements.

Email Marketing by

